Positive clinical results from hybryte™ compatibility study in the treatment of cutaneous t-cell lymphoma published in jeadv clinical practice

Published results confirm and extend response results from phase 3 flash study princeton, n.j. , may 16, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results of its compatibility study evaluating hybryte™ (synthetic hypericin) for the treatment of cutaneous t-cell lymphoma (ctcl) have been published in the journal of the european academy of dermatology & venereology (jeadv) clinical practice.
SNGX Ratings Summary
SNGX Quant Ranking